210 related articles for article (PubMed ID: 24346751)
1. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.
Soares CN; Fayyad RS; Guico-Pabia CJ
J Clin Psychopharmacol; 2014 Feb; 34(1):57-65. PubMed ID: 24346751
[TBL] [Abstract][Full Text] [Related]
2. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.
Soares CN; Endicott J; Boucher M; Fayyad RS; Guico-Pabia CJ
CNS Spectr; 2014 Dec; 19(6):519-27. PubMed ID: 24571916
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
4. Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
Soares CN; Wajsbrot DB; Boucher M
CNS Spectr; 2020 Jun; 25(3):363-371. PubMed ID: 31060632
[TBL] [Abstract][Full Text] [Related]
5. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
McIntyre RS; Fayyad R; Mackell JA; Boucher M
Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
[TBL] [Abstract][Full Text] [Related]
6. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
Kornstein SG; Guico-Pabia CJ; Fayyad RS
Hum Psychopharmacol; 2014 Sep; 29(5):492-501. PubMed ID: 25196042
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.
Liebowitz MR; Tourian KA; Hwang E; Mele L;
BMC Psychiatry; 2013 Mar; 13():94. PubMed ID: 23517291
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Liebowitz MR; Yeung PP; Entsuah R
J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
[TBL] [Abstract][Full Text] [Related]
9. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
Liebowitz MR; Manley AL; Padmanabhan SK; Ganguly R; Tummala R; Tourian KA
Curr Med Res Opin; 2008 Jul; 24(7):1877-90. PubMed ID: 18507895
[TBL] [Abstract][Full Text] [Related]
11. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
[TBL] [Abstract][Full Text] [Related]
12. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.
Rosenthal JZ; Boyer P; Vialet C; Hwang E; Tourian KA
J Clin Psychiatry; 2013 Feb; 74(2):158-66. PubMed ID: 23473348
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.
Tourian KA; Jiang Q; Ninan PT
CNS Spectr; 2010 Mar; 15(3):187-93. PubMed ID: 20414167
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
DeMartinis NA; Yeung PP; Entsuah R; Manley AL
J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
[TBL] [Abstract][Full Text] [Related]
16. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
Katzman MA; Nierenberg AA; Wajsbrot DB; Meier E; Prieto R; Pappadopulos E; Mackell J; Boucher M
J Clin Psychopharmacol; 2017 Oct; 37(5):555-561. PubMed ID: 28817491
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
[TBL] [Abstract][Full Text] [Related]
18. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
[TBL] [Abstract][Full Text] [Related]
20. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
